Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultra High Dose Diuretic Strategy for Acute Decompensated Heart Failure
NCT06036914Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Nov 2023
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bumetanide in heart failure (HF) (2 arms), sponsored by Mayo Clinic. Primary endpoint: Urine Output at 24 hours. Started Nov 2023; status: completed.
02
Drugs
bumetanide
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT06036914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06036914.